The role of catecholamines in modulating the secretion of adrenocorticotrophin (ACTH) has been investigated by numerous workers with conflicting results (van Loon, 1973) . In some of these studies l-DOPA has been used, which induces the production of adrenaline and noradrenaline in addition to that of dopamine. Recently 2-bromo-\g=a\-ergocryptine became available; this drug seems to be a more specific activator of the dopaminergic pathways in the central nervous system (Corrodi, Fuxe, H\l=o"\kfelt, Lidbrink & Ungerstedt, 1973 comparatively. In these four patients, plasma ACTH levels were significantly lower from 4 h after the administration of bromocriptine (P < 0025, paired f-test). Plasma cortisol levels were studied under the same circumstances in four patients (D,G and two others not shown). From 4 h after administration of bromocriptine, cortisol levels were significantly lower than on the control day: 14-0±4-l (S.D.) and 21-6±6-6ug/100ml respectively (P<0-01, 8 pairs of samples). In patient G, the plasma cortisol level 5 h after bromocriptine treatment was 18-5 compared with 35-9/ig/100ml on the control day, while in patient D, the levels of cortisol, like those of ACTH, remained almost identical (15-3 and 14-6^g /100ml respectively). In one of the patients (F), the clinical effect of bromocriptine was dramatic: 4 h after the administra¬ tion of the drug she experienced severe nausea and after 5 h she started vomiting. Blood pressure fell from 180/90 to 80/60 after 7h. The intravenous administration of 100 mg cortisol caused a rapid improvement of her condition. The other patients had no clinical effects or complaints after bromocriptine administration.
In two normal volunteers (controls), unstimulated plasma ACTH levels were studied during the day and no difference was found with and without bromocriptine (data not shown). In the two other controls, the maximal increase of plasma ACTH after lysine-vasopressin administra¬ tion was not changed by bromocriptine treatment (Table 2) . 
